Ten patients with pulmonary hydatid disease diagnosed on the basis of a chest radiograph and a positive response to the indirect haemagglutination test for hydatid disease were treated with albendazole 10 mg/kg/day for eight weeks.
Methods
From January 1986 to September 1989 we saw 13 patients at our hospital who were suspected of having pulmonary hydatid disease on the basis of a chest radiograph. In 10 of the patients the serological test for hydatid disease using an indirect haemagglutination assay gave a positive result (titre > 1:128); these patients were included in the study. Their age ranged from 17 to 40 years and their weight from 55 to 62 kg (mean weight 58 1 kg). All had had cough and scanty expectoration for 4-12 months. Five patients had had slight haemoptysis and four had dull chest pain. Seven patients underwent computed tomography of the chest, which showed daughter cysts inside the parent cyst. Three of the 10 patients had multiple cysts.
The patients were treated with albendazole (Alminth, Torrent Laboratories Ltd, Ahmadabad) 10 mg/kg daily in three divided doses after food for eight weeks. In the hope of increasing compliance, patients were asked to purchase the drug each week. however, three showed only a partial response and two failed to respond. Horton,' reviewing the combined experience of the use of albendazole to treat pulmonary hydatid cysts, noted that most patients had received 800 mg/day of albendazole in cycles of 28 days with a 14 days' interval and a mean of 2-5 cycles. Of the 86 patients with lung hydatid cysts (either alone or with other organs affected) 40% of the patients were cured and 35% showed improvement after albendazole treatment.
The dosage regimens for albendazole for the treatment of hydatid diseases have not been standardised; we used a dose of 10 mg/kg/day for two months. Most previous reports published in English have used the same dose for one to three months for lung or liver hydatid disease.89 Most of the cysticidal activity of albendazole appears to occur within the first two to three months of treatment, and if the cyst is not smaller after treatment for two months further drug treatment is unlikely to help.9
Side effects of albendazole include gastrointestinal side effects, alopecia, rash, leucopenia, and raised liver enzyme activities. In the review by Horton' 4% of patients given albendazole had haematological side effects and 17% had raised liver enzyme activities. None of these side effects was noted in our patients.
Serological results of medical treatment for hydatid disease have been reported in only a few studies. In one study, in which complement fixation tests gave positive results initially in three of four cases, two patients showed a fourfold rise in antibody titre with successful treatment.' In a study of nine patients antibody titres increased at least fourfold in all but one case, the increase occurring during or within three months of the end of treatment with albendazole.'0 An initial fall in serological titres did not predict clinical improvement. In the present study there was no change in antibody titres with treatment.
Surgery is the treatment of choice for hydatid disease of the lung unless there is a contraindication. A spontaneous cure occurs occasionally through rupture of the cyst into a bronchus, but the dangers of bronchial spread are too great to justify a waiting policy." Thus in our small open study albendazole at a dose of 10 mg/kg/day for eight weeks was ineffective in the treatment ofhydatid disease of the lung. The poor outcome, by comparison with some previous studies, could be due to differences in the pharmacokinetics of albendazole in our population or in the susceptibility of the cysts in the small numbers of patients in the different studies. Medical treatment should be considered possibly for patients in whom the cyst is inoperable because of dissemination or a difficult location or because surgery is contraindicated.
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